Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

EZN-2208

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
EZN‐2208 is a water‐soluble PEGylated conjugate of the topoisomerase inhibitor SN38, the active metabolite of irinotecan… Expand
2013
2013
Irinotecan is cytotoxic in patients with advanced colorectal cancer (CRC). SN‐38 (10‐hydroxy‐7‐ethyl‐camptothecin) is the active… Expand
2013
2013
PurposeThis study evaluated the tolerability, pharmacokinetics, and preliminary antitumor activity of EZN-2208, a water-soluble… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
2013
2013
SummaryBackground Anti-angiogenic therapies such as bevacizumab upregulate hypoxia-inducible factor-1α (HIF-1α), a possible… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
2012
2012
EZN‐2208 is a water‐soluble, polyethylene glycol drug conjugate of SN38, which is the active moiety of irinotecan. In this study… Expand
2012
2012
BRCA1 dysfunction in hereditary breast cancer causes defective homology-directed DNA repair and sensitivity towards DNA damaging… Expand
  • figure 1
  • figure 3
  • figure 4
2011
2011
Topoisomerase I inhibitors down-regulate HIF-1α leading to tumor growth inhibition, but only while maintaining sustained levels… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2010
Highly Cited
2010
Purpose: Treatment of neuroblastoma is successful in less than half of patients with high-risk disease. The antitumor activity of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
2009
2009
This paper decribes the results of preclinical animal model studies successfully treating human lymphoma xenografts using a… Expand
  • table 1
  • figure 2
  • figure 1
Highly Cited
2008
Highly Cited
2008
Purpose: Clinical development of SN38, the active metabolite of camptothecin-11 (CPT-11), has been hampered due to its poor… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • figure 3